Epizyme (EPZM) Tops Q3 EPS by 3c

Go back to Epizyme (EPZM) Tops Q3 EPS by 3c

RBC Affirms Epizyme (EPZM) at 'Outperform' as Ttazemetostat Enrollment Continues

November 9, 2015 12:43 PM EST

RBC Captial affirms Epizyme (Nasdaq: EPZM) at Outperform with a price target of $39 following Q3 results and update issued earlier.

Analyst Simos Simeonidis noted the following:

Enrollment continues in 150-patient Phase II study in NHL in Europe: On their 3Q15 earnings call this morning, management stated that plans remain on track for tazemetostat's Phase II programs. Patients are currently being enrolled in the 5-arm,... More

Trading Radar for 11/9: DISH Network (DISH), WhiteWave Foods (WWAV), Caesars (CZR), Plug Power (PLUG), Arch Coal (ACI) Report

November 6, 2015 2:39 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

Affiliated Managers Group (NYSE: AMG) - consensus EPS $2.87
Alnylam Pharma (Nasdaq: ALNY) - consensus loss $0.91
Altisource Residential (Nasdaq: RESI) - consensus EPS $0.39
Arch Coal (NYSE: ACI) - consensus loss $5.45
Atento S.A. (NYSE: ATTO) - consensus EPS $0.37
Avino Silver & Gold Mines (NYSE: ASM)... More